Skip to main content

Search

Reset all filters
318 Result(s)
Sort by

Ofev®

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Respiratory Diseases

Respiratory Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Lung Repair & Regeneration Video

Lung Repair & Regeneration Video

Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

NSCLC is the most common form of lung cancer. EGFR M+ NSCLC is a subtype of lung cancer and is identified via a mutation test. Find out more here.
Stargardt Disease

Stargardt Disease

Stargardt Disease is a hereditary condition causing and progressive vision loss, typically during childhood or adolescence.
IPF why wait?

IPF why wait?

IPF is a progressive and life threatening lung disease that can cause permanent damage in the lungs right from the start. Early diagnosis and treatment of IPF is critical, because acting quickly can make a difference.
Open Innovation at Boehringer Ingelheim

Open Innovation at Boehringer Ingelheim

Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
New approaches in the battle against heartworm disease

New approaches in the battle against heartworm disease

Heartworm disease is a concern to dog and cat owners worldwide. Current disease control methods are increasingly challenged by drug resistance. We explore the potential for novel treatments and vaccines based on new knowledge and technology.
Cardiometabolic Diseases

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.